Meeting
2018 ASCO Annual Meeting
TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.
Authors
Vinod Ravi
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Vinod Ravi , Andrew Scott Brohl , Sant P. Chawla , Steven Attia , Richard F. Riedel , David A. Liebner , Katherine Anne Thornton , Atrayee Basu Mallick , Cyrus R. Mehta , Lingyun Liu , Delia Alvarez , Charles P. Theuer , Steven Ian Robinson , Nicolas Penel , Silvia Stacchiotti , William D. Tap , Robin Lewis Jones , Robert G. Maki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02979899
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS11590)
DOI
10.1200/JCO.2018.36.15_suppl.TPS11590
Abstract #
TPS11590
Poster Bd #
333a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).
First Author: Robin Lewis Jones
Poster
2015 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).
First Author: Steven Attia
First Author: Michelino De Laurentiis
Poster
2022 ASCO Annual Meeting
Feasibility of an explainable AI-based therapeutic recommendation-tool utilizing tumor gene expression profiles in advanced and refractory solid tumors.
First Author: Ouissam Al Jarroudi